Posts

Roche Terminates Phase 2 SHIELD DMD Study for Satralizumab in Duchenne Bone Health

on
Roche announced on February 20, 2026, the termination of the Phase 2 SHIELD DMD study (NCT06450639) evaluating satralizumab for bone health in Duchenne muscular dystrophy. The decision was due to low recruitment (fewer than 30 boys enrolled across six countries), study timelines, and no realistic path to regulatory approval, not safety or efficacy issues. The study will continue until interim data collection, after which it will close; Roche committed to sharing interim data at a future medical conference. In the US, eight individuals are currently enrolled. This news was shared via a community letter and reported by organizations like Parent Project Muscular Dystrophy and CureDuchenne. Sources:

Novo Nordisk's CagriSema Underperforms Eli Lilly's Zepbound in Head-to-Head Phase 3 Obesity Trial

on

Spinogenix's SPG302 ALS Drug Shows Positive Phase IIa Results, Advances to Registrational Trial Amid Lingering Questions

on

Slate Medicines Launches with $130M Series A for Anti-PACAP Migraine Drug from China's DartsBio

on

Jake Leach Named Chair of AdvaMed's Diabetes Sector

on

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

on

Biopharma Bites: FDA Reviews Roche and Teva NDAs, Candel Funding

on

Gilead Sciences Acquires Arcellx in $7.8 Billion Deal to Control CAR-T Cell Therapy

on

Vanda Pharmaceuticals Receives FDA Approval for Bysanti (Milsaperidone) for Schizophrenia and Bipolar I Disorder

on

Grail's Galleri Cancer Test Misses Primary Endpoint in NHS Trial, Shares Plunge Despite Positive Trends

on

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod at ECCO 2026 Alongside IBD Clinical Data

on

'Just Agree to It': Pazdur Claims Pressure to Cosign FDA's Single-Trial Policy Shift

on

Verily Expands AI Health Platform Pre with New Datasets and Free Self-Serve Tools

on